LUTATHERA Market Share

Nov 29, 2024

Radioligand therapies are rapidly transforming the neuroendocrine tumor treatment landscape, offering new hope to patients and reshaping the market dynamics. This innovative approach, which combines the precision of targeted therapy with the potency of radiation, is gaining significant traction in the oncology comm...

Apr 26, 2024

2024 could be an eventful year for LUTATHERA and radioligand therapies (RLTs) around their future commercial prospects.  On April 23, 2024, the FDA approved LUTATHERA (lutetium Lu 177 dotatate) for the treatment of pediatric patients aged 12 years and older with somatostatin receptor (SSTR)-positive gastro-...